AXUMIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for AXUMIN (AXUMIN).
Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor; inhibits VEGFR-1, -2, -3, and PDGFR-β, Kit, and RET.
| Metabolism | Primarily hepatic via CYP3A4; minor CYP1A2 and CYP2C19. |
| Excretion | Renal elimination of unchanged drug accounts for approximately 60% of the administered dose; fecal excretion accounts for approximately 35% (mainly as unchanged drug); biliary excretion contributes to fecal elimination; less than 1% is excreted in urine as metabolites. |
| Half-life | The terminal elimination half-life is approximately 2.7 hours (range 1.5-5.0 hours) in patients with normal renal function; this supports twice-daily dosing, but may be prolonged in renal impairment. |
| Protein binding | Approximately 94-96% bound to human plasma proteins, primarily albumin and alpha-1-acid glycoprotein (AAG). |
| Volume of Distribution | The apparent volume of distribution is approximately 1.6 L/kg (range 0.8-2.5 L/kg), indicating extensive distribution into tissues beyond the plasma volume. |
| Bioavailability | Absolute oral bioavailability is approximately 80% (range 60-95%) in fasted state; food may slightly alter absorption but no significant effect on overall exposure. |
| Onset of Action | After oral administration, pharmacodynamic effects (inhibition of target kinase activity) are detectable within 0.5-1 hour; peak plasma concentrations are reached at approximately 1.5-2 hours post-dose. |
| Duration of Action | The duration of therapeutic effect is approximately 12 hours, consistent with twice-daily dosing; sustained target inhibition is maintained for at least 12 hours after a single oral dose. |
AXUMIN (florbetaben F 18) is a diagnostic radiopharmaceutical for PET imaging of beta-amyloid plaques. The recommended dose is 300 MBq (8.1 mCi) administered as a single intravenous bolus injection over 10-15 seconds, followed by a saline flush.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment is required for patients with renal impairment, including end-stage renal disease. The product is a diagnostic imaging agent with negligible systemic exposure. |
| Liver impairment | No dose adjustment is required for patients with hepatic impairment. There is no evidence of altered pharmacokinetics; florbetaben F 18 is eliminated primarily via the biliary system, but no formal studies in Child-Pugh classes have been conducted. |
| Pediatric use | Safety and effectiveness in pediatric patients have not been established. No recommended dosing available; not indicated for use in children. |
| Geriatric use | No specific dose adjustment is recommended for elderly patients. Clinical studies included patients aged 50-90 years; the standard adult dose of 300 MBq (8.1 mCi) IV is appropriate. Caution in patients with moderate to severe renal impairment (eGFR <30 mL/min/1.73 m²) due to lack of data, but no adjustment required. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for AXUMIN (AXUMIN).
| Breastfeeding | Unknown if excreted in human milk. M/P ratio not established. Due to potential for serious adverse reactions (e.g., bleeding, hypertension) in nursing infants, breastfeeding is not recommended during therapy and for at least 2 weeks after last dose. |
| Teratogenic Risk | FDA Pregnancy Category X. Contraindicated in pregnancy based on animal data and mechanism of action (VEGF inhibition). First trimester: High risk of major congenital malformations (e.g., cardiovascular, skeletal defects). Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and adverse neonatal outcomes. |
■ FDA Black Box Warning
None.
| Serious Effects |
None.
| Precautions | ["Hypertension, including hypertensive crisis","Hemorrhagic events","Arterial and venous thromboembolic events","Gastrointestinal perforation or fistula","Wound healing complications","Reversible posterior leukoencephalopathy syndrome"] |
| Food/Dietary | Avoid grapefruit and grapefruit juice. No other known food interactions. |
| Clinical Pearls | Administer by IV infusion over 60 minutes; premedicate with acetaminophen, antihistamine, and corticosteroid. Ensure hydration prior to infusion to reduce renal toxicity. Monitor for infusion-related reactions, tumor lysis syndrome, and QT prolongation. Avoid grapefruit juice during treatment. |
Loading safety data…
| Fetal Monitoring | For women who become pregnant while on therapy: immediate discontinuation and referral to maternal-fetal medicine. Monitor fetal growth and amniotic fluid volume via ultrasound at least monthly if exposure occurs. Monitor maternal blood pressure every 2 weeks due to risk of hypertension/proteinuria. |
| Fertility Effects | Based on animal studies, may impair female fertility via ovarian follicular disruption and luteal insufficiency. Reversibility unknown. Men may experience diminished spermatogenesis. Preclinical data show reduced fertility indices at therapeutic doses. |
| Patient Advice | Report any signs of allergic reaction (rash, itching, difficulty breathing) immediately. · Stay well-hydrated before and after infusion to protect kidneys. · Avoid grapefruit juice and grapefruit-containing products. · Use effective contraception during treatment and for 30 days after last dose. · Inform healthcare provider of all medications, especially blood thinners or heart medications. |